Evidence map›Paper›PMID 36938318›Full record

ArticleContemporary clinical trials communications2023

Precision recruitment for high-risk participants in a COVID-19 cohort study.

Aziz M Mezlini, Eamon Caddigan, Allison Shapiro, Ernesto Ramirez, Helena M Kondow-McConaghy, Justin Yang, Kerry DeMarco, Pejman Naraghi-Arani, Luca Foschini

Open access · goldAbstract read
In one paragraph

Article in Contemporary clinical trials communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Aziz M MezliniEvidation Health, Inc., 63 Bovet Rd. #146, San Mateo, CA 94402, USA.
Eamon CaddiganEvidation Health, Inc., 63 Bovet Rd. #146, San Mateo, CA 94402, USA.
Allison ShapiroEvidation Health, Inc., 63 Bovet Rd. #146, San Mateo, CA 94402, USA.
Ernesto RamirezEvidation Health, Inc., 63 Bovet Rd. #146, San Mateo, CA 94402, USA.
Helena M Kondow-McConaghyOak Ridge Institute of Science and Education, 1299 Bethel Valley Rd, Oak Ridge, TN 37830, USA.
Justin YangBiomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, US Department of Health and Human Services, 200 Independence Ave., Washington, DC 20201, USA.
Kerry DeMarcoBiomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, US Department of Health and Human Services, 200 Independence Ave., Washington, DC 20201, USA.
Pejman Naraghi-AraniBiomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, US Department of Health and Human Services, 200 Independence Ave., Washington, DC 20201, USA.
Luca FoschiniEvidation Health, Inc., 63 Bovet Rd. #146, San Mateo, CA 94402, USA.
Evidation Health (United States) · USBiomedical Advanced Research and Development Authority · USOak Ridge Associated Universities · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Studies for developing diagnostics and treatments for infectious diseases usually require observing the onset of infection during the study period. However, when the infection base rate incidence is low, the cohort size required to measure an effect becomes large, and recruitment becomes costly and prolonged. We developed a model for reducing recruiting time and resources in a COVID-19 detection study by targeting recruitment to high-risk individuals. Methods: We conducted an observational longitudinal cohort study at individual sites throughout the U.S., enrolling adults who were members of an online health and research platform. Through direct and longitudinal connection with research participants, we applied machine learning techniques to compute individual risk scores from individually permissioned data about socioeconomic and behavioral data, in combination with predicted local prevalence data. The modeled risk scores were then used to target candidates for enrollment in a hypothetical COVID-19 detection study. The main outcome measure was the incidence rate of COVID-19 according to the risk model compared with incidence rates in actual vaccine trials. Results: When we used risk scores from 66,040 participants to recruit a balanced cohort of participants for a COVID-19 detection study, we obtained a 4- to 7-fold greater COVID-19 infection incidence rate compared with similar real-world study cohorts. Conclusion: This risk model offers the possibility of reducing costs, increasing the power of analyses, and shortening study periods by targeting for recruitment participants at higher risk.

Indexed as

CDC, Centers for Disease Control and PreventionClinical trialsCOVID-19GAMs, generalized additive modelsRisk modeling

Identifiers

PMID36938318
PMCPMC10008035
OpenAlexW4323922544

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.